# Advantages of Ciprofol with Special Consideration of Pediatric Anesthesia

**Authors:** Alessandro Vittori, Cecilia Di Fabio, Marco Cascella, Franco Marinangeli, Elisa Francia, Ilaria Mascilini, Cecilia Maria Pizzo, Corrado Cecchetti, Valentina Di Conza, Teresa Grimaldi Capitello, Giuliano Marchetti, Giuseppe Servillo, Pasquale Buonanno

PMC · DOI: 10.3390/children13020188 · 2026-01-29

## TL;DR

Ciprofol is a promising anesthetic for children due to its pain-free use and stable effects.

## Contribution

The paper highlights ciprofol's potential advantages in pediatric anesthesia compared to existing agents.

## Key findings

- Ciprofol provides pain-free induction and hemodynamic stability in pediatric patients.
- It reduces emergence delirium and respiratory depression in children.
- Adult studies support ciprofol's safety and effectiveness, suggesting potential for pediatric use.

## Abstract

The search for an ideal anesthetic has always been a major goal in anesthesiology. In recent years, the introduction of ciprofol has marked a major breakthrough in the pharmacological field, following the introduction of dexmedetomidine. Ciprofol has similar characteristics to propofol but with greater hemodynamic stability. Furthermore, it overcomes one of the most common discomforts associated with propofol: pain at the injection site. These characteristics make it a suitable hypnotic for pediatric use. Although studies on children are still limited, the literature on adults is now substantial and of high quality. The potential advantages of using ciprofol in pediatric anesthesia include pain-free induction, hemodynamic stability, less respiratory depression, and a lower incidence of emergence delirium.

## Linked entities

- **Chemicals:** ciprofol (PubChem CID 86301664), propofol (PubChem CID 4943), dexmedetomidine (PubChem CID 5311068)

## Full-text entities

- **Genes:** KNG1 (kininogen 1) [NCBI Gene 3827] {aka BDK, BK, HAE6, HK, HMWK, KNG}, KLK4 (kallikrein related peptidase 4) [NCBI Gene 9622] {aka AI2A1, ARM1, EMSP, EMSP1, KLK-L1, PRSS17}, GABARAP (GABA type A receptor-associated protein) [NCBI Gene 11337] {aka ATG8A, GABARAP-a, MM46}, SIRT3 (sirtuin 3) [NCBI Gene 23410] {aka SIR2L3}, UGT1A9 (UDP glucuronosyltransferase family 1 member A9) [NCBI Gene 54600] {aka HLUGP4, LUGP4, UDPGT, UDPGT 1-9, UGT-1I, UGT1-09}, CST3 (cystatin C) [NCBI Gene 1471] {aka ADLDWA, ARMD11, HEL-S-2}, CYP2B6 (cytochrome P450 family 2 subfamily B member 6) [NCBI Gene 1555] {aka CPB6, CYP2B, CYP2B7, CYPIIB6, EFVM, IIB1}
- **Diseases:** abnormal limb movement (MESH:D001259), supraventricular tachycardia (MESH:D013617), apnea (MESH:D001049), decrease (MESH:D009123), rhabdomyolysis (MESH:D012206), metabolic acidosis (MESH:D000138), Agitation (MESH:D011595), cardiovascular complications (MESH:D002318), gastrointestinal diseases (MESH:D005767), hepatic or renal toxicity (MESH:D056486), cardiac (MESH:D006331), renal or hepatic failure (MESH:D017093), postoperative nausea and vomiting (MESH:D020250), renal impairment (MESH:D007674), depression (MESH:D003866), cognitive dysfunction (MESH:D003072), hypertriglyceridemia (MESH:D015228), sepsis (MESH:D018805), memory deficits (MESH:D008569), prolonged QTcF (MESH:D008133), Pain (MESH:D010146), cardiovascular and respiratory depression (MESH:D012140), ASA I-III (MESH:D056807), shock (MESH:D012769), injury (MESH:D014947), inflammation (MESH:D007249), complication (MESH:D008107), PRIS (MESH:D000072736), critically ill (MESH:D016638), postoperative cognitive impairment (MESH:D000079690), sinus bradycardia (MESH:D012804), central nervous system syndrome (MESH:D002493), anxiety (MESH:D001007), multiorgan failure (MESH:D051437), Cancer (MESH:D009369), hip arthroplasty (MESH:D025981), delirium (MESH:D003693), metabolic toxicity (MESH:D065606), respiratory depression (MESH:D012131), POD (MESH:D000071257), nausea (MESH:D009325), arrhythmia (MESH:D001145), organ injuries (MESH:D009102), sedative (MESH:C535788), bradycardia (MESH:D001919), muscle fasciculations (MESH:D005207), disorganization (MESH:D012562), hypoxemia (MESH:D000860), vomiting (MESH:D014839), hypotension (MESH:D007022)
- **Chemicals:** benzodiazepines (MESH:D001569), rocuronium (MESH:D000077123), 2,6-disubstituted phenols (-), S (MESH:D013455), Lidocaine (MESH:D008012), amine (MESH:D000588), chloride ion (MESH:D002713), Alfentanil (MESH:D015760), dexmedetomidine (MESH:D020927), lipid (MESH:D008055), oxygen (MESH:D010100), glucuronide (MESH:D020719), carbon (MESH:D002244), fentanyl (MESH:D005283), phenol (MESH:D019800), Remifentanil (MESH:D000077208), chloride (MESH:D002712), Propofol (MESH:D015742), norepinephrine (MESH:D009638), glutamate (MESH:D018698)
- **Species:** Rodentia (rodent, order) [taxon 9989], Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939459/full.md

---
Source: https://tomesphere.com/paper/PMC12939459